EBR Systems Ltd (ASX: EBR) disappointed investors this week when it announced it had implanted just 40 WiSE systems during the quarter, below its own forecast.

The company’s shares are now down almost 90% over a 12-month period, but according to the analyst teams at both Bell Potter and Morgans, there’s upside to be had from there.

It’s just that the two brokers differ wildly on how much upside there will be.

Quarterly report fell short of expectations

I’ll get to the specifics of their predictions shortly. First let’s have a closer look at what the company reported this week.

EBR Systems has developed the world’s only wireless cardiac pacing device for heart failure – the WiSE system – and is in the early stages of its commercial roll out.

In the third quarter the number of implantations was below previous quarters, with the company saying a change in management at its US operations, a change in strategy, and additional field training requirements led to the decline.

EBR systems said it was recruiting to build out its commercial team in the US, with numerous searches under way.

The company said:

EBR continues to refocus field management and activities around deeper utilisation within activated accounts, increased procedural frequency and strengthened field training and support. These initiatives are intended to strengthen U.S. commercial execution, with benefits expected to build progressively as additional field training is completed and account activity increases.

During the quarter EBR also completed the final tranche of a $150 million capital raising.

Shares looking cheap, or very cheap

Morgans said in its research note on the company that it understood a new sales strategy was needed.

They said:

Notably, WiSE adoption requires a sustained, high-touch sales effort, with representatives previously focused on prioritising the opening of new sites rather than supporting existing accounts and generating repeat procedures. Management is redirecting resources towards activated centres, strengthening territory accountability and changing its sales training model, with early feedback encouraging.

Morgans said there was little visibility of sales going forward, with the company reporting encouraging signs in early October, but giving no formal guidance.

They added:

We continue to see value in WiSE’s differentiated technology, clinical utility and substantial potential market opportunity. However, disappointing execution, greater commercial intensity and uncertain adoption trajectory warrant more conservative forecasts and a materially lower valuation. We see the potential for a recovery in commercial momentum, although the investment case now hinges on evidence of execution rather than the theoretical size of the opportunity.

Morgans lowered their price target from $1.95 to $1.20, which is still 757.1% higher than the current price of 14 cents.

Bell Potter, on the other hand, lowered their price target from 70 cents to 20 cents, which would be a 42.9% return if achieved.

EBR Systems is valued at $131 million.

The post This ASX biotech could rise 40% or 750%, depending on who you ask appeared first on The Motley Fool Australia.

More reading

• This ASX biotech could nearly triple in value Bell Potter says

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Alcoa Corporation Ltd (ASX: AAI) share price is under the spotlight following the company’s third quarter 2026 results, which featured net income of $483 million and continued strong operational performance.

What did Alcoa report?

• Revenue of $3.7 billion for Q3 2026, down 7% from Q2 2026
• Net income attributable to Alcoa Corporation rose to $483 million (Q2 2026: $407 million)
• Adjusted net income: $485 million; adjusted earnings per share: $1.82
• Adjusted EBITDA (excluding special items): $789 million
• Free cash flow of $472 million for the quarter
• Cash balance of $4.4 billion, including $2.6 billion in financing for the AliGroup acquisition

What else do investors need to know?

Alcoa increased aluminium production for the sixth consecutive quarter, with five smelters and one refinery hitting year-to-date volume records. The company completed the restart of its Alumar smelter in Brazil, supporting higher output.

The major AliGroup acquisition from South32 advanced significantly, with funding secured and South32 shareholders approving the deal. The transaction is tracking for completion in the first half of 2027.

Alcoa also entered into agreements to sell portions of its Massena East site in New York, targeting up to $315 million in potential proceeds over the next seven years, conditional on project developments.

What’s next for Alcoa?

Alcoa reaffirmed its 2026 alumina and aluminium production and shipment forecasts, expecting further gains in the fourth quarter as stability continues across its refineries and smelters. Management anticipates steady Alumina segment margins and some cost headwinds in the Aluminium segment due to higher raw material costs and scheduled maintenance.

The company aims to close the AliGroup acquisition in early 2027, integrate these assets, and continue efforts to optimise its operating portfolio. Higher interest income from acquisition cash reserves and an increased annual interest expense are on the radar for Q4 and beyond.

Alcoa share price snapshot

Over the past 12 months, Acola shares have risen 6%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has fallen 2% over the same period.

View Original Announcement

The post Alcoa posts higher net income, sets sights on AliGroup completion appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Deep Yellow Ltd (ASX: DYL) share price is in focus after the company announced it will delay its Final Investment Decision (FID) for the Tumas uranium project in Namibia beyond Q4 2026, but reports strong progress on construction and key civil works.

What did Deep Yellow report?

• Final Investment Decision for Tumas project postponed due to current equity market conditions
• Civil and concrete works at Tumas are fully funded with existing cash reserves
• 170 tonnes of reinforcing steel installed; all major concrete pouring areas prepared
• Four local contracts awarded worth A$3.7 million to support ongoing construction
• Environmental Clearance Certificates renewed until 2029
• 440 contractor and employee safety inductions completed

What else do investors need to know?

Deep Yellow is pushing ahead with on-site civil works at Tumas, with concrete pouring underway and off-site pre-casting of wall panels progressing as scheduled. The company highlights that these construction activities are fully funded and represent a key step in systematically de-risking the project ahead of FID.

Local economic participation has also been a focus, with contracts awarded to Namibian businesses for fuel, water, waste management, and dust suppression services. Safety remains a priority, demonstrated by comprehensive health, environment, and risk management training for the site workforce.

What did Deep Yellow management say?

Managing Director and CEO Greg Field said:

Tumas is a world-class, fully permitted uranium project in a Tier 1 jurisdiction that will play a key role in providing the next generation of supply of this key decarbonisation fuel. Despite the compelling global uranium market fundamentals, challenging equity market conditions continue to constrain funding options for uranium developers. Against this backdrop, we believe it is prudent to defer FID beyond Q4 2026 while maintaining construction momentum and progressing our funding strategy to ensure Tumas is well positioned to advance when market conditions improve. The commencement of civil works on schedule represents another significant milestone for Tumas, reflecting the considerable progress achieved across engineering, procurement and construction readiness as we systematically de-risk the project’s development. I am extremely pleased with the progress being made and the dedication and commitment of our team, which is now translating into tangible progress on the ground.

What’s next for Deep Yellow?

Deep Yellow plans to finalise and release an optimisation study and updated economic assessment for Tumas, which will inform the next phase of its development. The company is keeping construction moving at a steady pace, aiming to benefit when equity market conditions improve and to ensure Tumas is ready for the next major investment decision.

Looking further ahead, Deep Yellow remains focused on developing both its Namibian and West Australian project portfolios as part of its mission to become a globally diversified uranium producer.

Deep Yellow share price snapshot

Over the past 12 months, Deep Yellow shares have declined 67%, trailing the S&P/ASX 200 Index (ASX: XJO), which has fallen 3% over the same period.

View Original Announcement

The post Deep Yellow updates on Tumas project progress, delays FID appeared first on The Motley Fool Australia.

More reading

• Own ASX mining shares? Official forecasts show commodity prices peaking in FY27
• Here are the top 10 ASX 200 shares today
• 3 ASX shares tipped to fly 109% to 322% higher
• Buy, hold, sell: Deep Yellow, SGH, Telstra shares
• This ASX uranium stock could rise 40%: Broker

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.